Hormonal, Metabolic and Signaling Interactions in PAH

描述：肺动脉高压(PAH)影响着数以千计的各个年龄段的美国人，年轻女性的疾病比例更高。尽管最近取得了进展，但PAH在3年内夺走了三分之一患者的生命。我们的初步研究表明，包括雌激素代谢改变和胰岛素抵抗在内的一系列复杂的事件相互作用，导致能量产生缺陷、细胞内异常运输和细胞骨架缺陷，这些缺陷表征和促进了PAH的心血管功能障碍。我们计划的中心主题是干预下游机制，我们已经证明这些机制在PAH发病机制中很重要，目前已经有翻译治疗可用。我们的假设是，对PAH背后的代谢途径功能障碍的最佳治疗将改善肺血管功能和疾病的后果。我们的目标是开发高效的治疗方法，这对合并许多常见心肺疾病的肺动脉高压也有好处。在项目1中，我们将使用多种方法验证2-甲氧基雌二醇作为治疗PAH的方法，包括流行病学和雌激素代谢物平衡对肺血管和心脏功能的功能研究。这将证实和扩大研究表明，雌激素代谢从2-羟基化转向16-α-羟化导致女性体内多环芳烃过量。在项目2中，我们将使用包括代谢表型、流行病学和患者干预在内的多种方法，测试二甲双胍作为治疗PAH的方法，扩大我们在PAH中胰岛素抵抗和代谢综合征的发现。在项目3中，我们将继续将ACE2作为治疗PAH的方法，延续了我们之前的发现，即ACE2是对小鼠BMPR2相关PAH的有效干预。结合Vanderbilt PAH计划内的其他研究，我们计划在第二个五年期间为这些治疗方法的临床试验做好准备。这些治疗方法中的每一种都是针对最近发现的疾病的基本致病机制。这一新的计划直接建立在多环芳烃机制的最新发现基础上，以开发针对阻断这些生物途径的疗法。

DESCRIPTION: Pulmonary arterial hypertension (PAH) affects thousands of Americans of all ages, with disproportionate disease in young women. Despite recent progress PAH takes the lives of a third of all patients within 3 years. Our preliminary studies indicate that a complicate interplay of events, including altered estrogen metabolism and insulin resistance, drive energy production defects, abnormal intracellular trafficking, and cytoskeletal defects which characterize and promote the cardiovascular dysfunction characteristic of PAH. The central theme of our program is to intervene against downstream mechanisms which we have shown to be important in PAH pathogenesis and for which translational therapies are currently available. Our hypothesis is that optimal treatment of the dysfunctional metabolic pathways which underlie PAH will improve pulmonary vascular function and consequences of the disease. Our goal is to develop highly effective therapy, which will also have benefit for pulmonary hypertension which complicates many common heart and lung diseases. In Project 1 we will validate 2-methoxyestradiol as a treatment for PAH using multiple approaches, including epidemiology and functional studies of estrogen metabolite balance on lung vascular and cardiac function. This will confirm and extend studies demonstrating that diversion of estrogen metabolism away from 2-hydoxylation and towards 16α-hydroxylation contributes to excess PAH in females. In Project 2, we will test metformin as a treatment for PAH, extending our findings of insulin resistance and metabolic syndrome in PAH, using multiple approaches including metabolic phenotyping, epidemiology, and patient interventions. In project 3, we will pursue ACE2 as a treatment for PAH, extending our previous finding that ACE2 is an effective intervention in murine BMPR2-related PAH. In combination with other studies within the Vanderbilt PAH program, we plan for each of these treatments to be ready for clinical trials during a second five year period. Each of these treatments is targeted at recently identified basic pathogenetic mechanisms of disease. This novel program builds directly on recent discoveries of PAH mechanisms to develop therapeutics targeted to interdict those biologic pathways.